🧬 Health & Longevity
An AI-Discovered Drug Reached Phase 2: What Rentosertib Proved — and Didn't
Rentosertib produced an encouraging signal in a small pulmonary-fibrosis trial. It also shows why AI cannot skip clinical evidence.
🧬 All articles in
Health & Longevity
Medical robotics, AI-designed drugs, brain interfaces and the evidence behind longevity research.
🧬 Health & Longevity
Autonomous Surgery in 2026: What Robots Can Really Do Without a Surgeon
A research robot completed a complex procedure on realistic tissue models. Today's cleared surgical systems remain under direct physician control.
🧬 Health & Longevity
Can Big Tech Slow Aging? What Alphabet's Calico Is Actually Building
Alphabet-backed Calico studies the biology of aging, but its public clinical pipeline is about specific diseases—not immortality.
🧬 Health & Longevity
Brain Implants in 2026: Neuralink, Synchron and the Reality Behind the Demos
Early feasibility studies are testing whether people with severe paralysis can control digital devices. That is not mind reading or human enhancement.
🧬 Health & Longevity
New Cancer Medicines in 2026: Targeted Advances, Not a Universal Cure
Recent U.S. approvals show how cancer treatment is becoming more precise: a defined tumour, biomarker and treatment history—not one medicine for every cancer.
🧬 Health & Longevity
The First Cellular-Rejuvenation Trial Has Begun: What ER-100 Is Really Testing
ER-100 is testing partial epigenetic reprogramming in up to 18 people with optic-nerve disease. It is a local phase 1 safety study, not whole-body rejuvenation.
🧬 Health & Longevity
Hair-Regrowth Drugs in 2026: PP405, Clascoterone and the Real Evidence
PP405 aims to reactivate dormant follicles and clascoterone targets local androgen signalling. Both remain investigational for hair loss despite positive company releases.
🧬 Health & Longevity
Neuralink's Robot-Arm Trial: What CONVOY Is Actually Testing
CONVOY extends Neuralink's brain implant from cursor control to an assistive robotic arm. It is a three-person early feasibility study, not restored biological movement.
🧬 Health & Longevity
Obesity Drugs in 2026: The New GLP-1 Pill, Retatrutide and the Safety Gap
Orforglipron is now approved in the United States, while retatrutide remains investigational. The gap matters as unapproved versions spread online.
🧬 Health & Longevity
Senolytics in 2026: What Human Trials Actually Show
Drugs that clear senescent cells are being tested in people, but today's studies are small and do not prove longer life.
🧬 Health & Longevity
Can a Drug Regrow Teeth? What Japan's TRG035 Program Has—and Hasn't—Proved
TRG035 targets a pathway that suppresses tooth development. Animal evidence exists, but public 2026 trial-status pages are inconsistent and no approved tooth-regrowth drug exists.